Top Research Reports for Eli Lilly, Netflix & GE Aerospace
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Source: NASDAQ.COM
Research Reports on Major Stocks: Zacks Research Daily highlights reports on 16 major stocks, including Eli Lilly, Netflix, and GE Aerospace, showcasing their performance and challenges in the market, particularly focusing on new product demand and competition.
Market Insights and Economic Data: The article emphasizes the importance of the 'Ahead of Wall Street' section for investors, providing insights into economic releases and their potential impact on daily trading actions, alongside a big week of inflation data and Q2 earnings reports.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 919.770
Low
950.00
Averages
1192
High
1500
Current: 919.770
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Shares Near $900, Stock Split Speculation Grows
- Stock Price Near $900: Eli Lilly's shares are hovering just below the $900 mark, reflecting market confidence in its future growth, with speculation about a stock split potentially attracting a broader investor base.
- Strong Drug Sales Growth: The company's GLP-1 drugs, Mounjaro and Zepbound, are projected to generate nearly $23 billion and $13.5 billion in revenue respectively for 2025, with year-over-year growth rates of 99% and 175%, indicating robust market demand and significant growth potential.
- Low Market Penetration: Despite strong adoption, GLP-1 drug penetration among the eligible obesity population in the U.S. remains in the mid-single digits, suggesting substantial growth opportunities for Eli Lilly's obesity portfolio, especially with the upcoming launch of oral GLP-1 therapy orforglipron.
- Optimistic Future Revenue Outlook: Eli Lilly is guiding for fiscal 2026 revenue between $80 billion and $83 billion, and while management anticipates pricing pressures on revenue growth, strong volume growth is expected to more than offset this, highlighting the broad-based and durable demand for its drugs.
See More
Trump Threatens Increased Sanctions on Iran
- Market Reaction: Futures fell sharply as President Trump announced that the U.S. would impose stricter sanctions on Iran over the next 2-3 weeks, reflecting investor concerns about geopolitical risks.
- Oil Price Surge: Following Trump's statement, oil prices jumped, indicating heightened expectations of potential supply disruptions that could impact global energy market stability.
- Geopolitical Tensions: Trump's tough rhetoric escalates tensions in the Middle East, potentially leading to further deterioration in international relations and affecting U.S. foreign policy with other nations.
- Investor Sentiment: The uncertainty in the market dampens investor sentiment, likely resulting in capital outflows from high-risk assets towards safer investments, thereby impacting overall market performance.
See More
Indian Markets Rattle Amid Iran War Turmoil
- Foreign Capital Exodus: Amid the turmoil of the Iran war, Indian markets experienced a record foreign investor sell-off exceeding $12 billion in March, resulting in a more than 10% drop in the Nifty 50 index, highlighting significant concerns over future economic growth prospects.
- Diminished Growth Outlook: India's Chief Economic Advisor V. Anantha Nageswaran warned that rising energy costs and supply chain disruptions pose considerable downside risks to the forecasted 7.0%-7.4% growth for FY 2027, with expectations of a significant widening of the trade deficit exacerbating fiscal pressures.
- Government Intervention: In response to economic strains, the Indian government implemented two key measures, including limiting banks' currency-hedging positions and cutting excise duties on petrol and diesel by 10 rupees per liter, which will significantly impact tax revenues and potentially hinder government spending capabilities.
- Weak Job Market: While India's consumption narrative continues to attract foreign investment, the lack of white-collar job creation undermines this story, with reports indicating that only a small percentage of graduates secure stable employment within a year of graduation, posing a long-term challenge to economic growth.
See More
Eli Lilly Secures FDA Approval for New Weight-Loss Drug
- FDA Approval: Eli Lilly announced that its weight-loss drug Foundayo received FDA approval, becoming the first daily oral weight-loss medication, which is expected to be highly popular and pushed the stock price up nearly 4%, significantly outperforming the S&P 500's 0.7% gain.
- Product Launch Plan: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, likely attracting many consumers seeking weight-loss solutions and further increasing the company's market share.
- Market Competition Analysis: Compared to Novo Nordisk's Wegovy, Foundayo has lower reported weight-loss results in clinical trials, but its more stable molecule and flexible dosing schedule may make it more appealing to consumers, enhancing its competitive edge in the market.
- Significant Marketing Potential: Eli Lilly possesses substantial marketing resources, which are expected to effectively drive the acceptance of Foundayo in the market; combined with its leadership position in the weight-loss drug sector, this could lead to a notable increase in stock price.
See More
Eli Lilly Wins FDA Approval for Foundayo Weight-Loss Pill
- FDA Approval: Eli Lilly has received FDA approval for its weight-loss drug Foundayo, which is a daily oral medication, marking a significant breakthrough for the company in the weight-loss market and is expected to attract a large consumer base.
- Positive Market Reaction: The announcement led to a nearly 4% increase in Eli Lilly's stock price, significantly outperforming the S&P 500's 0.7% gain, indicating strong investor confidence in the new product.
- Clear Product Advantages: Foundayo offers a sturdier molecular structure and more flexible dosing compared to Novo Nordisk's Wegovy, although it has shown slightly lower weight-loss results in clinical trials; however, its convenience may attract more users.
- Innovative Sales Channel: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, which is expected to enhance the company's market share and brand influence.
See More
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
Eli Lilly Shares Near $900, Stock Split Speculation Grows
- Stock Price Near $900: Eli Lilly's shares are hovering just below the $900 mark, reflecting market confidence in its future growth, with speculation about a stock split potentially attracting a broader investor base.
- Strong Drug Sales Growth: The company's GLP-1 drugs, Mounjaro and Zepbound, are projected to generate nearly $23 billion and $13.5 billion in revenue respectively for 2025, with year-over-year growth rates of 99% and 175%, indicating robust market demand and significant growth potential.
- Low Market Penetration: Despite strong adoption, GLP-1 drug penetration among the eligible obesity population in the U.S. remains in the mid-single digits, suggesting substantial growth opportunities for Eli Lilly's obesity portfolio, especially with the upcoming launch of oral GLP-1 therapy orforglipron.
- Optimistic Future Revenue Outlook: Eli Lilly is guiding for fiscal 2026 revenue between $80 billion and $83 billion, and while management anticipates pricing pressures on revenue growth, strong volume growth is expected to more than offset this, highlighting the broad-based and durable demand for its drugs.
See More
Trump Threatens Increased Sanctions on Iran
- Market Reaction: Futures fell sharply as President Trump announced that the U.S. would impose stricter sanctions on Iran over the next 2-3 weeks, reflecting investor concerns about geopolitical risks.
- Oil Price Surge: Following Trump's statement, oil prices jumped, indicating heightened expectations of potential supply disruptions that could impact global energy market stability.
- Geopolitical Tensions: Trump's tough rhetoric escalates tensions in the Middle East, potentially leading to further deterioration in international relations and affecting U.S. foreign policy with other nations.
- Investor Sentiment: The uncertainty in the market dampens investor sentiment, likely resulting in capital outflows from high-risk assets towards safer investments, thereby impacting overall market performance.
See More
Indian Markets Rattle Amid Iran War Turmoil
- Foreign Capital Exodus: Amid the turmoil of the Iran war, Indian markets experienced a record foreign investor sell-off exceeding $12 billion in March, resulting in a more than 10% drop in the Nifty 50 index, highlighting significant concerns over future economic growth prospects.
- Diminished Growth Outlook: India's Chief Economic Advisor V. Anantha Nageswaran warned that rising energy costs and supply chain disruptions pose considerable downside risks to the forecasted 7.0%-7.4% growth for FY 2027, with expectations of a significant widening of the trade deficit exacerbating fiscal pressures.
- Government Intervention: In response to economic strains, the Indian government implemented two key measures, including limiting banks' currency-hedging positions and cutting excise duties on petrol and diesel by 10 rupees per liter, which will significantly impact tax revenues and potentially hinder government spending capabilities.
- Weak Job Market: While India's consumption narrative continues to attract foreign investment, the lack of white-collar job creation undermines this story, with reports indicating that only a small percentage of graduates secure stable employment within a year of graduation, posing a long-term challenge to economic growth.
See More
Eli Lilly Secures FDA Approval for New Weight-Loss Drug
- FDA Approval: Eli Lilly announced that its weight-loss drug Foundayo received FDA approval, becoming the first daily oral weight-loss medication, which is expected to be highly popular and pushed the stock price up nearly 4%, significantly outperforming the S&P 500's 0.7% gain.
- Product Launch Plan: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, likely attracting many consumers seeking weight-loss solutions and further increasing the company's market share.
- Market Competition Analysis: Compared to Novo Nordisk's Wegovy, Foundayo has lower reported weight-loss results in clinical trials, but its more stable molecule and flexible dosing schedule may make it more appealing to consumers, enhancing its competitive edge in the market.
- Significant Marketing Potential: Eli Lilly possesses substantial marketing resources, which are expected to effectively drive the acceptance of Foundayo in the market; combined with its leadership position in the weight-loss drug sector, this could lead to a notable increase in stock price.
See More
Eli Lilly Wins FDA Approval for Foundayo Weight-Loss Pill
- FDA Approval: Eli Lilly has received FDA approval for its weight-loss drug Foundayo, which is a daily oral medication, marking a significant breakthrough for the company in the weight-loss market and is expected to attract a large consumer base.
- Positive Market Reaction: The announcement led to a nearly 4% increase in Eli Lilly's stock price, significantly outperforming the S&P 500's 0.7% gain, indicating strong investor confidence in the new product.
- Clear Product Advantages: Foundayo offers a sturdier molecular structure and more flexible dosing compared to Novo Nordisk's Wegovy, although it has shown slightly lower weight-loss results in clinical trials; however, its convenience may attract more users.
- Innovative Sales Channel: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, which is expected to enhance the company's market share and brand influence.
See More
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
